Biograil Raises €20M for Oral Drug Delivery Trial Prep

Good Laboratory Practice studies and a manufacturing process rarely get top billing in a biotech financing. At Biograil, they explain where the new money is going: the Danish developer of capsule-based drug delivery announced a €20M financing on November 4, 2026, backed by Verve Ventures, Megatrend Invest and HTGF through its HTGF Opportunity growth fund.

The company is preparing its BIONDD technology for planned Phase 1 testing. Nonclinical studies and manufacturing preparation sit between an oral-delivery idea and the human evidence that pharmaceutical developers need to make decisions about it.

Biograil's proposition reaches beyond the capsule itself. Giving a drug developer another way to administer a biologic could change the product it develops and the routine a patient eventually follows, provided the technology advances through clinical development. The financing brings that ambition into the less photogenic work of studies, processes and repeatable production.

What Biograil is financing before Phase 1

Biograil says the proceeds will support nonclinical GLP studies and establishment of a Good Manufacturing Practice process ahead of a larger financing planned for 2027. Those are preparatory commitments, with clinical testing still ahead in the company's account. The announcement does not provide a trial-start date or identify an approved BIONDD product.

The investor continuity is worth reading carefully. HTGF led the company's seed syndicate in 2019 and is now participating through its Opportunity growth fund, while Verve Ventures and Megatrend Invest continue backing the business. The latest release identifies the investors without assigning a lead or a numbered financing series, so the €20M remains a financing round rather than an inferred Series B.

Biograil previously announced an €8.5M first closing in July 2025, led by Verve Ventures. That history shows investors had already been funding preparations for clinical testing. The releases do not supply a reconciled lifetime funding figure, and adding the two headlines would create an accounting claim the company has not established.

For pharmaceutical partners, the manufacturing work gives the financing a practical meaning. A delivery system has to become something a development programme can use consistently. Paying for that capability carries the company toward a different kind of conversation with the organisations evaluating its technology.

The engineering inside the oral capsule

BIONDD's design places a drug-delivery device inside a conventional capsule. The company describes the capsule dissolving in the stomach, where a spring-loaded mechanism positions the device against the gastric wall and delivers the medicine into tissue for systemic distribution. The device is designed to detach and continue through the gastrointestinal tract after delivery.

That mechanism matters because the familiar act of swallowing a capsule conceals a difficult delivery problem. Many large therapeutic molecules face degradation and poor absorption in the digestive tract, as the researchers explain in their original BIONDD study. Biograil's approach uses physical delivery into the stomach wall to give the payload a route past those barriers.

The paper, published in May 2026, reports experiments with liraglutide in dogs and exposure comparable to subcutaneous injection. It supplies a preclinical research foundation for the platform. Human performance and tolerability remain questions for clinical development, and the financing announcement describes preparations for that work rather than completed human results.

Biograil also describes injection moulding as central to the platform's manufacturing approach. That choice connects the capsule's design to the business of producing it: a pharmaceutical partner evaluating delivery needs to understand the device and the process that makes it. The funded manufacturing preparation puts those two responsibilities alongside the scientific programme.

Founders, investors and the development handoff

Biograil was established in 2019, and its current team page identifies Karsten Lindhardt as co-founder and CEO and Nikolaj Skak as co-founder and CSO. Morten Revsgaard Frederiksen is CTO. Those roles place scientific development and device engineering within the same leadership group as the company works toward clinical entry.

The company's official address is in Roskilde, Denmark, while its announcements describe it as Copenhagen based. That geography puts a specific team and operating location behind the broader oral-delivery proposition. Biograil is building a pharmaceutical development business around a device, with the manufacturing and regulatory work that combination brings into its day-to-day priorities.

Verve Ventures' health and bio investment thesis includes technologies for producing and delivering biological medicines. Biograil fits that interest through the administration route it is developing. For the returning investor group, continued financing keeps the existing team moving through a development stage whose outputs should become more useful to potential partners.

The commercial opportunity is easiest to understand from the partner's side. A pharmaceutical developer may have a molecule worth advancing and still need a workable way to administer it. Biograil is seeking a place in that decision, with a platform whose value will depend on the evidence and manufacturing capability accompanying each proposed application. Its next stretch of work brings the laboratory result, the capsule and the production process closer to the same clinical programme.